Background The majority of available data on molnupiravir come from an unvaccinated
COVID-19 population. Therefore, we conducted this meta-analysis to integrate evidence …

The efficacy of molnupiravir in treating patients with coronavirus disease 2019 (COVID‐19)
has been inconsistent across randomized controlled trials (RCTs). Thus, this meta‐analysis …

Background Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …

Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …

Introduction There are currently some differences in the research results of molnupiravir.
This study aimed to evaluate the efficacy and safety of molnupiravir in the treatment of …

Objectives Previous research reported inconsistent results on the efficacy of molnupiravir in
treating COVID-19. Moreover, efficacy was not assessed in the intended-use population …

Background Molnupiravir (MOL) is an oral antiviral medication that has recently been treated
for COVID-19. Objectively We perform a prospective and observational study to elucidate the …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Introduction: The coronavirus disease 2019 (COVID-19) pandemic started in March 2020.
Since then, there has been an urgent need for effective therapeutic methods to manage the …